Advertisement

Topics

AstraZeneca drug gets breakthrough status in early lung cancer

22:37 EDT 30 Jul 2017 | Reuters

LONDON (Reuters) - AstraZeneca said on Monday its immunotherapy drug Imfinzi had been granted "breakthrough" designation by U.S. regulators for treating non-metastatic lung cancer, following the success of the so-called Pacific trial.

Original Article: AstraZeneca drug gets breakthrough status in early lung cancer

NEXT ARTICLE

More From BioPortfolio on "AstraZeneca drug gets breakthrough status in early lung cancer"

Quick Search
Advertisement
 

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Biological Therapy
Biological therapy involves the use of living organisms, substances derived from living organisms, or laboratory-produced versions of such substances to treat disease. Some biological therapies for cancer use vaccines or bacteria to stimulate the body&rs...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...